

# Vecihi Batuman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3257836/publications.pdf>

Version: 2024-02-01

102  
papers

6,517  
citations

101543

36  
h-index

64796

79  
g-index

105  
all docs

105  
docs citations

105  
times ranked

6548  
citing authors

#	ARTICLE	IF	CITATIONS
1	Aristolochic acid I induces proximal tubule injury through <sc>ROS</sc>/<sc>HMGB1</sc>/mt <sc>DNA</sc> mediated activation of <sc>TLRs</sc>. Journal of Cellular and Molecular Medicine, 2022, 26, 4277-4291.	3.6	8
2	The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4. American Journal of the Medical Sciences, 2021, 362, 453-461.	1.1	8
3	The Proximal Tubule Toxicity of Immunoglobulin Light Chains. Kidney International Reports, 2021, 6, 1225-1231.	0.8	16
4	Accuracy of Ankle-Brachial Index, Toe-Brachial Index, and Risk Classification Score in Discriminating Peripheral Artery Disease in Patients With Chronic Kidney Disease. American Journal of Cardiology, 2021, 160, 117-123.	1.6	2
5	Cell spinpods are a simple inexpensive suspension culture device to deliver fluid shear stress to renal proximal tubular cells. Scientific Reports, 2021, 11, 21296.	3.3	2
6	Paraproteins. , 2020, , 53-58.e3.		0
7	Free light chains injure proximal tubule cells through the STAT1/HMGB1/TLR axis. JCI Insight, 2020, 5, .	5.0	14
8	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
9	Animal models of monoclonal immunoglobulin-related renal diseases. Nature Reviews Nephrology, 2018, 14, 246-264.	9.6	43
10	Fatal Hypermagnesemia Due to Laxative Use. American Journal of the Medical Sciences, 2018, 355, 390-395.	1.1	27
11	Anemia and risk for cognitive decline in chronic kidney disease. BMC Nephrology, 2016, 17, 13.	1.8	46
12	Paraproteinâ€“Related Kidney Disease: Kidney Injury from Paraproteinsâ€“What Determines the Site of Injury?. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2288-2294.	4.5	63
13	Renoprotective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide 38 (PACAP38). Current Topics in Neurotoxicity, 2016, , 289-312.	0.4	3
14	Non-diabetic renal disease in diabetic patients: How to identify? When to biopsy?. Journal of Diabetes and Its Complications, 2015, 29, 613-614.	2.3	1
15	Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrology, 2015, 16, 77.	1.8	106
16	Novel Treatments and the Future of Diabetic Nephropathy: What Is on the Horizon?. , 2014, , 241-250.		0
17	The Persistence of Chronic Lead Nephropathy. American Journal of Kidney Diseases, 2014, 64, 1-3.	1.9	8
18	Incidence and predictive factors of Balkan Endemic Nephropathy: A longitudinal study. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2014, 25, 343.	0.3	2

#	ARTICLE	IF	CITATIONS
19	Pituitary adenylate cyclase-activating polypeptide prevents contrast-induced nephropathy in a novel mouse model. <i>Physiological Reports</i> , 2013, 1, e00163.	1.7	16
20	Fifteenth national congress of the Turkish Society of Hypertension and Renal Diseases. <i>Kidney International Supplements</i> , 2013, 3, 307.	14.2	0
21	Hypertension and chronic kidney disease in Turkey. <i>Kidney International Supplements</i> , 2013, 3, 308-311.	14.2	4
22	Salt and hypertension: why is there still a debate?. <i>Kidney International Supplements</i> , 2013, 3, 316-320.	14.2	24
23	Prostaglandin D2 synthase: Apoptotic factor in alzheimer plasma, inducer of reactive oxygen species, inflammatory cytokines and dialysis dementia. <i>Journal of Nephropathology</i> , 2013, 2, 166-80.	0.2	13
24	Receptor-Associated Protein Blocks Internalization and Cytotoxicity of Myeloma Light Chain in Cultured Human Proximal Tubular Cells. <i>PLoS ONE</i> , 2013, 8, e70276.	2.5	13
25	Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3176-3181.	0.7	63
26	Renal Ischemia and Transplantation Predispose to Vascular Constriction Mediated by Angiotensin II Type 1 Receptor-Activating Antibodies. <i>Transplantation</i> , 2012, 94, 8-13.	1.0	57
27	Delayed administration of pituitary adenylate cyclase-activating polypeptide 38 ameliorates renal ischemia/reperfusion injury in mice by modulating Toll-like receptors. <i>Peptides</i> , 2012, 38, 395-403.	2.4	18
28	The Pathogenesis of Acute Kidney Impairment in Patients With Multiple Myeloma. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 282-286.	1.4	25
29	The role of a parental history of Balkan endemic nephropathy in the occurrence of BEN: a prospective study. <i>International Journal of Nephrology and Renovascular Disease</i> , 2012, 5, 61.	1.8	6
30	The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. <i>Nature Reviews Nephrology</i> , 2012, 8, 43-51.	9.6	226
31	Salt and Hypertension: An Evolutionary Perspective. <i>Journal of Hypertension: Open Access</i> , 2012, 01, .	0.2	5
32	Role of Proximal Tubules in the Pathogenesis of Kidney Disease. <i>Contributions To Nephrology</i> , 2011, 169, 37-50.	1.1	71
33	Renoprotection With Pituitary Adenylate Cyclase-Activating Polypeptide in Cyclosporine A-Induced Nephrotoxicity. <i>Journal of Investigative Medicine</i> , 2011, 59, 793-802.	1.6	18
34	Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 920-923.	4.7	31
35	Pituitary Adenylate Cyclase-Activating Polypeptide Prevents Cisplatin-Induced Renal Failure. <i>Journal of Molecular Neuroscience</i> , 2011, 43, 58-66.	2.3	26
36	Reduced Kidney Size in Adult Offspring of Balkan Endemic Nephropathy Patients and Controls: A Prospective Study. <i>American Journal of the Medical Sciences</i> , 2010, 340, 94-102.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Emergence of biomarkers in nephro pharmacology. <i>Biomarkers in Medicine</i> , 2010, 4, 805-814.	1.4	29
38	Myeloma Light Chain-Induced Renal Injury in Mice. <i>Nephron Experimental Nephrology</i> , 2010, 116, e32-e41.	2.2	14
39	Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury. <i>Peptides</i> , 2010, 31, 592-602.	2.4	27
40	The Effect of PACAP38 on MyD88-Mediated Signal Transduction in Ischemia/Hypoxia-Induced Acute Kidney Injury. <i>American Journal of Nephrology</i> , 2010, 32, 522-532.	3.1	35
41	Offspring of parents with Balkan Endemic Nephropathy have higher C-reactive protein levels suggestive of inflammatory processes: a longitudinal study. <i>BMC Nephrology</i> , 2009, 10, 10.	1.8	8
42	Myeloma kidney with isolated tubulointerstitial light chain deposition in a renal allograft. <i>Clinical Transplantation</i> , 2009, 23, 848-852.	1.6	9
43	Vitamin D: a new hope for chronic kidney disease?. <i>Kidney International</i> , 2009, 76, 1219-1221.	5.2	13
44	Myeloma kidney: toward its prevention—with new insights from in vitro and in vivo models of renal injury. <i>Journal of Nephrology</i> , 2009, 22, 17-28.	2.0	27
45	Microalbuminuria as a possible marker of risk of Balkan endemic nephropathy. <i>Nephrology</i> , 2008, 13, 616-621.	1.6	4
46	Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. <i>Regulatory Peptides</i> , 2008, 145, 24-32.	1.9	51
47	Estimated burden of blood lead levels $\geq 45 \mu\text{g/dl}$ in 1999–2002 and declines from 1988 to 1994. <i>Environmental Research</i> , 2008, 107, 305-311.	7.5	33
48	Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F82-F90.	2.7	68
49	Lead chelation therapy retards the decline of renal function in patients with chronic kidney disease. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 646-647.	2.0	2
50	Association between the metabolic syndrome and chronic kidney disease in Chinese adults. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1100-1106.	0.7	138
51	Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 860-870.	0.7	58
52	Parathyroid Hormone Status Does Not Influence Blood and Bone Lead Levels in Dialysis Patients. <i>American Journal of the Medical Sciences</i> , 2007, 334, 415-420.	1.1	6
53	Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: A case study. <i>Peptides</i> , 2007, 28, 1891-1895.	2.4	76
54	Association of tibia lead and blood lead with end-stage renal disease: A pilot study of African-Americans. <i>Environmental Research</i> , 2007, 104, 396-401.	7.5	26

#	ARTICLE	IF	CITATIONS
55	The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. <i>Clinical Transplantation</i> , 2007, 21, 583-589.	1.6	11
56	Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. <i>Blood</i> , 2006, 107, 661-668.	1.4	71
57	Stranded with the Patients: A Nephrologist's Remembrances of Hurricane Katrina. <i>American Journal of the Medical Sciences</i> , 2006, 332, 255-258.	1.1	1
58	Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate. <i>Annals of Internal Medicine</i> , 2006, 144, 172.	3.9	192
59	Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. <i>Kidney International</i> , 2006, 69, 644-646.	5.2	52
60	Treatment of Renal Failure Associated with Multiple Myeloma and Other Diseases by PACAP-38. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 1-4.	3.8	29
61	Proximal Tubular Injury in Myeloma. , 2006, 153, 87-104.		63
62	Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells. <i>Cancer Research</i> , 2006, 66, 8796-8803.	0.9	27
63	Blood Lead Below 0.48 $\mu\text{mol/L}$ (10 $\mu\text{g/dL}$ ) and Mortality Among US Adults. <i>Circulation</i> , 2006, 114, 1388-1394.	1.6	392
64	Continued Decline in Blood Lead Levels Among Adults in the United States. <i>Archives of Internal Medicine</i> , 2005, 165, 2155.	3.8	256
65	HIV-associated renal disorders: Recent insights into pathogenesis and treatment. <i>Current HIV/AIDS Reports</i> , 2005, 2, 109-115.	3.1	20
66	Light chains are a ligand for megalin. <i>Journal of Applied Physiology</i> , 2005, 98, 257-263.	2.5	77
67	Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic. <i>Archives of Internal Medicine</i> , 2005, 165, 936.	3.8	307
68	The risk for mild kidney function decline associated with illicit drug use among hypertensive men. <i>American Journal of Kidney Diseases</i> , 2004, 43, 629-635.	1.9	44
69	The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults. <i>Annals of Internal Medicine</i> , 2004, 140, 167.	3.9	1,170
70	Blood lead and chronic kidney disease in the general United States population: Results from NHANES III. <i>Kidney International</i> , 2003, 63, 1044-1050.	5.2	186
71	Edema in the Nephrotic Syndrome: New Aspect of an Old Enigma. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 3288-3289.	6.1	17
72	Blood Lead Level Is Associated With Elevated Blood Pressure in Blacks. <i>Hypertension</i> , 2003, 41, 463-468.	2.7	106

#	ARTICLE	IF	CITATIONS
73	Effect of Blood Pressure on Early Decline in Kidney Function Among Hypertensive Men. <i>Hypertension</i> , 2003, 42, 1144-1149.	2.7	74
74	Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 469-477.	6.1	331
75	Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, F1245-F1254.	2.7	77
76	Serum Antioxidant Vitamins and Blood Pressure in the United States Population. <i>Hypertension</i> , 2002, 40, 810-816.	2.7	94
77	Use of recombinant hirudin as an anticoagulant in plasmapheresis in a patient with heparin-induced thrombocytopenia. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1533-a-1534.	0.7	1
78	Relationship of serum antioxidant vitamins to serum creatinine in the US population. <i>American Journal of Kidney Diseases</i> , 2002, 39, 460-468.	1.9	23
79	Endocytosis of light chains induces cytokines through activation of NF- $\kappa$ B in human proximal tubule cells. <i>Kidney International</i> , 2002, 62, 1977-1988.	5.2	110
80	Acute tubulointerstitial nephritis after wasp stings. <i>American Journal of Kidney Diseases</i> , 2001, 38, E33.	1.9	33
81	Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. <i>American Journal of Kidney Diseases</i> , 2000, 36, 735-744.	1.9	55
82	Myeloma light chains are ligands for cubilin (gp280). <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, F246-F254.	2.7	70
83	Phosphate transport inhibition by KW-3902, an adenosine A1 receptor antagonist, is mediated by cyclic adenosine monophosphate. <i>American Journal of Kidney Diseases</i> , 1995, 26, 825-830.	1.9	23
84	Low-Molecular-Weight Protein Competition for Binding Sites on Renal Brush Border Membranes. <i>Kidney and Blood Pressure Research</i> , 1994, 17, 287-293.	2.0	5
85	Effect of KW-3902, a novel adenosine A1 receptor antagonist, on sodium-dependent phosphate and glucose transport by the rat renal proximal tubular. <i>Life Sciences</i> , 1994, 55, 839-845.	4.3	33
86	Effect of Myeloma Light Chains on Phosphate and Glucose Transport in Renal Proximal Tubule Cells. <i>Kidney and Blood Pressure Research</i> , 1994, 17, 294-300.	2.0	12
87	Lead Nephropathy, Gout, and Hypertension. <i>American Journal of the Medical Sciences</i> , 1993, 305, 241-247.	1.1	76
88	Cell volume changes in filtration studies of red cell deformability. <i>Clinical Hemorheology and Microcirculation</i> , 1991, 11, 295-302.	1.7	1
89	Effect of alpha interferon on glucose and alanine transport by rat renal brush border membrane vesicles. <i>Life Sciences</i> , 1990, 47, 1187-1193.	4.3	1
90	Effects of Chronic Peritoneal Dialysis on Thyroid Function Tests. <i>American Journal of Kidney Diseases</i> , 1989, 13, 99-103.	1.9	31

#	ARTICLE	IF	CITATIONS
91	Lead Increases Red Cell Sodium-Lithium Countertransport. American Journal of Kidney Diseases, 1989, 14, 200-203.	1.9	12
92	Reducing bone lead content by chelation treatment in chronic lead poisoning: An in vivo X-ray fluorescence and bone biopsy study. Environmental Research, 1989, 48, 70-75.	7.5	31
93	Two-dimensional echocardiographic findings in patients on hemodialysis for more than six months. American Journal of Cardiology, 1987, 60, 743-745.	1.6	30
94	Light chain effects on alanine and glucose uptake by renal brush border membranes. Kidney International, 1986, 30, 662-665.	5.2	33
95	Renal and Electrolyte Effects of Total Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 1984, 8, 546-551.	2.6	13
96	The safety of the EDTA lead-mobilization test. Environmental Research, 1983, 30, 58-62.	7.5	39
97	Contribution of Lead to Hypertension with Renal Impairment. New England Journal of Medicine, 1983, 309, 17-21.	27.0	185
98	Effect of Antitubular Basement Membrane and Brush Border Antibodies on <i>p</i><i>A</i>minohippurate Transport in Kidney. Nephron, 1981, 29, 258-264.	1.8	2
99	The Role of Lead in Gout Nephropathy. New England Journal of Medicine, 1981, 304, 520-523.	27.0	156
100	Geophagic lead nephropathy: Case report. Environmental Research, 1978, 17, 409-415.	7.5	20
101	Relation of Tubular Interstitial Disease to Renal Function. Contributions To Nephrology, 1978, 11, 10-13.	1.1	1
102	ANTIDIURETIC ACTION OF CHLORPROPAMIDE. Lancet, The, 1973, 302, 684.	13.7	0